Company* |
Product | Description |
Indication | Status |
| | ||||
AUTOIMMUNE | ||||
Astralis Ltd. |
Psoraxine |
Protein-based immunostimulator |
Psoriasis |
Phase II trial in 120 patients with moderate to severe psoriasis showed no statistically significant symptom improvement vs. placebo (3/14) |
BioCryst |
BCX-4208 |
Second-generation, transitiontate analogue inhibitor of purine nucleoside phosphorylase |
Psoriasis |
Phase I trial in 85 volunteers demonstrated tolerability and a dose-related inhibition of PNP (3/15) |
Connetics |
Primolux (OLUX-EF) |
Clobetasol propionate; topical steroid |
Psoriasis and atopic dermatitis |
Began Phase III program that will include a Phase III trial in each indication (3/24) |
Merrimack |
MM-093 |
Recombinant version of human alpha-fetoprotein; an immunomodulator |
Rheumatoid arthritis |
Began Phase II trial to examine safety and efficacy in about 240 patients (3/3) |
Rigel |
R406 |
Oral syk kinase inhibitor that blocks activation of mast cells, macrophages and B cells |
Rheumatoid arthritis |
Phase I trial in 59 volunteers showed the drug was well tolerated, and established a correlation between R406 plasma levels and inhibition of its target (3/31) |
The Immune |
NeuroVax |
T-cell receptor peptide vaccine |
Multiple sclerosis |
Began a Phase II trial in 40 patients to investigate long-term safety, mechanism of action and utility of a quarterly dosing regimen (3/1) |
CANCER | ||||
Advanced Viral |
AVR118 |
Peptide-nucleic acid complex with immuno-modulatory properties |
Advanced cancers |
Began Phase II trial to examine safety, tolerability and efficacy in 40 patients (3/14) |
Adventrx |
CoFactor |
Form of folic acid designed to enhance the antitumor effects of 5-FU |
Metastatic colorectal cancer |
Phase II trial with 5-FU met its primary endpoint for response rate (3/7) |
AmpliMed |
Amplimexon |
Imexon injection; believed to disrupt mitochondria |
Advanced pancreatic adenocarcinoma |
Began a Phase I/II trial in combination with gemcitabine that initially will assess dosing and toxicity (3/3) |
Callisto |
Atiprimod |
Drug designed to inhibit VEGF and interleukin-6 |
Advanced cancers |
Began open-label trial to evaluate dosing and activity in cancer patients (3/15) |
Celgene |
Revlimid |
Lenalidomide; derivative of Thalomid (thalidomide) |
Multiple myeloma |
Two Phase III trials exceeded the pre- specified p<0.0015 value for the primary endpoint of time to disease progression; Revlimid plus dexamethasone was tested against dexamethasone alone (3/7) |
Cell |
Xyotax |
Paclitaxel linked to biodegradable polyglutamate polymer |
Ovarian cancer |
Began Phase III trial to test safety and efficacy in 1,550 patients who have achieved a complete remission following chemotherapy (3/22) |
Cell |
Xyotax |
Paclitaxel linked to biodegradable polyglutamate polymer |
Non-small-cell lung cancer |
Phase III Stellar3 trial did not meet its primary endpoint, but showed statistical significance with carboplatin for non- nferiority of survival vs. paclitaxel and carboplatin; side effects also were reduced (3/7) |
Exelixis Inc. |
XL880 |
Small-molecule spectrum- selective kinase inhibitor; inhibits Met and VEGFR2 |
Cancers |
Began Phase I trial in patients with solid tumors for whom there are no available therapies known to prolong survival (3/17) |
Genentech |
Avastin (FDA-approved) |
Bevacizumab; antibody designed to inhibit vascular endothelial growth factor |
Non-small-cell lung cancer |
Phase III trial with paclitaxel and carboplatin in first-line non-squamous NSCLC met its primary end-point of improving overall survival vs. chemotherapy alone (3/14) |
Generex |
AE37 |
HER-2/neu therapeutic vaccine |
Breast cancer |
Began trial in 16 to 24 patients that will assess immunological responses for one year (3/22) |
Genetronics |
MedPulser Tumor Ablation System |
Electroporation-mediated method for delivering DNA-based therapies |
Pancreatic cancer |
Began Phase I trial in up to 12 paients to test safety and other endpoints of the therapy with bleomycin in advanced disease (3/1) |
Geron Corp. |
Telomerase therapeutic vaccine |
Metastatic |
Telomerase-specific T-cell responses were successfuly generated in 19 of 20 patients in the Phase I/II trial, and there was a significant increase in PSA doubling time (3/4) |
|
Gloucester |
FK228 |
Depsipeptide; histone deacetylase inhibitor |
Cutaneous T-cell lymphoma |
Began a pivotal trial under an FDA SPA; details on the trial were not disclosed (3/1) |
Inotek |
INO-1001 |
Inhibitor of the nuclear cell death enzyme poly (ADP-ribose) polymerase |
Glioblastoma |
Began Phase Ib/IIa trial to assess tolerability, safety and pharmacokinetics (3/8) |
Introgen |
INGN 241 |
Agent containing the tumor- suppressor gene Mda-7/IL-24 |
Solid tumors |
Phase I trial in 22 patients with advanced tumors showed clinical responses in 44% of the treated lesions (3/17) |
Ligand |
Targretin (FDA-approved) |
Bexarotene capsules; selective retinoid X receptor modulator |
Non-small-cell lung cancer |
Pivotal Phase III SPIRIT I and II trial in front-line combination therapy in advanced patients did not improve overall survival or projected two-year survival (3/28) |
Medarex Inc. |
MDX-010 |
Fully human anti-CTLA-4 antibody |
Metastatic |
Eight of 36 patients in a Phase I/II trial experienced objective clinical responses (three complete, five partial) (3/7) |
Millennium |
Velcade (FDA-approved) |
Bortezomib; proteasome inhibitor |
Multiple myeloma |
Began Phase IV EVEREST re-treatment trial in up to 120 patients who previously responded to the drug and relapsed following a treatment-free remission (3/10) |
Morphotek |
MORAb-003 |
Monoclonal antibody that has high specificity for a number of cancers |
Advanced ovarian cancer |
Began Phase I trial to test dosing and safety in patients with chemo-refractive disease (3/29) |
Myriad |
MPC-6827 |
Pro-apoptotic drug candidate |
Metastatic brain cancer agent in the brain (3/1) |
Began Phase I trial to assess the therapeutic concentrations of the (MYGN) |
NovaDel |
Lingual spray from of ondansetron hydrochloride (GlaxoSmithKline plc's Zofran) |
Chemotherapy- induced nausea and vomiting |
Pilot pharmacokinetic trial demonstrated the ability to deliver the drug via the lingual spray technology (3/16) |
|
Onyx |
BAY 43-9006 (sorafenib) |
RAF kinase and VEGF inhibitor |
Advanced kidney cancer |
Phase III trial met surrogate endpoint of statistically significant and longer progression-free survival Bayer Pharmaceuticals Corp. vs. placebo; they plan to prepare an NDA, and also to continue the trial to test overall survival (3/8) |
Onyx |
BAY 43-9006 (sorafenib) |
RAF kinase and VEGF inhibitor |
Advanced liver cancer |
Began Phase III trial to measure overall survival, time to symptom progression and time to tumor progression vs. placebo in more than 500 patients (3/8) |
Spectrum |
EOquin |
Bioreductive prodrug |
Superficial |
Complete responses were seen in 29 of 41 previously treated patients in a Phase II trial (3/16) |
SuperGen |
Orathecin |
Rubitecan; topoisomerase-I inhibitor in capsule formulation |
Advanced pancreatic cancer |
Began Phase II trial with gemcitabine as a first-line treatment in 30 chemotherapy-naïve patients (3/3) |
Vion |
Cloretazine (VNP40101M) |
Sulfonyl hydrazine DNA alkylating agent |
Acute myelogenous leukemia |
Began pivotal Phase III in relapsed patients under an FDA SPA that will evaluate response rates with Ara-C vs. Ara-C and placebo (3/28) |
Vion |
Cloretazine |
Sulfonyl hydrazine DNA alkylating agent |
Acute myelogenous leukemia and myelodysplatic |
Phase II trial in 67 elderly AML and 14 high- risk MDS patients showed a response rate of 30%; a response rate of 7% was seen in 44 patients with relapsed AML (3/21) |
Viventia |
Proxinium |
Antibody fragment conjugated with a cancer- killing payload |
Refractory head |
Phase I monotherapy trial showed four of 16 evaluable patients who expressed the therapeutic target had a complete response, 10 had an objective response and 14 had tumor growth control (3/29) |
YM |
TheraCIM h-R3 |
Humanized anti-epidermal growth factor receptor monoclonal antibody |
Advanced glioma in children |
Got FDA OK to test the drug in one child; a larger study is being planned (3/16) |
CARDIOVASCULAR | ||||
Affymax Inc.* |
Hematide |
Peptide-based erythrpoiesis-stimulating agent |
Anemia |
Phase I trial demonstrated dose- dependent increases in circulating reticulocytes, as well as safety and tolerability (3/9) |
Amgen |
Aranesp (FDA-approved) |
Darbepoetin alfa, a recombinant erythropoietic protein |
Anemia |
Began TREAT trial in 4,000 patients to assess whether treating anemia reduces cardiovascular events in those with chronic kidney disease and Type II diabetes (3/28) |
Corautus |
VEGF-2 |
Vascular endothelial growth factor-2 in the form of naked plasmid DNA |
Severe angina |
Monitors in Phase IIb GENASIS trial recommended continuation following an interim safety analysis of 54 patients (3/30) |
Corautus |
VEGF-2 |
Vascular endothelial growth factor-2 in the form of naked plasmid DNA |
Severe angina |
Two-year follow-up from Phase I trial showed statistically significant prolonged benefit of improvement of angina two years following treatment (3/8) |
Corgentech |
E2F Decoy (edifoligide) |
Oligonucleotide designed to inactivate the cell-cycle transcription factor E2F |
To prevent vein graft |
Phase III PREVENT IV trial in 3,014 patients failed to reduce the incidence of graft failure vs. placebo; secondary endpoints were not met, either (3/30) |
CoTherix Inc. |
Ventavis (FDA-approved) |
Inhaled formulation of iloprost, a prostacyclin analogue |
Pulmonary arterial hypertension |
STEP trial with Tracleer in 65 pat- ients demonstrated clinical benefit in a number of endpoints (3/8) |
DeCode |
DG041 |
Small-molecue antagonist of the EP3 receptor for prostaglandin E2 |
Peripheral arterial occlusive disease |
Began Phase I trial that will assess safety, pharmacokinetics and pharmacodynamics (3/9) |
Dyax Corp. |
DX-88 |
Recombinant small protein designed to inhibit human plasma kallikrein |
Hereditary angioedema |
Began a trial in normal volunteers to evaluate the safety and pharmacokinetics of a subcutaneous route of administration (3/28) |
GenVec Inc. |
Transplantation of autologous myoblast cells |
Congestive heart failure |
Three-year follow-up data from Phase I trial in 30 patients showed the procedure is feasible and safe (3/8) |
|
GenVec Inc. |
BioBypass |
Vascular endothelial growth factor used to stimulate the growth of new blood vessels |
Severe coronary artery disease |
Began Phase IIb NOVA trial to evaluate the product in 129 patients with chest pain due to the disease (3/2) |
Guilford |
Aggrastat (FDA-approved) |
Tirofiban hydrochloride; glycoprotein IIb/IIIa receptor antagonist |
For use in |
Additional data from ADVANCE trial showed improved outcomes vs. placebo in diabetic patients undergoing PCI (3/8) |
Isis |
ISIS 301012 |
Capsule formulation of second-generation anti-sense inhibitor of ApoB-100 |
Cholesterol |
Began Phase I trial to assess oral bioavailability, safety and pharmacological effects of the drug in healthy volunteers (3/15) |
Lev |
C1-INH |
C1-esterase inhibitor |
Hereditary angioedema |
Began Phase III trial to examine the drug in treating acute attacks and in preventing the onset of such attacks (3/15) |
Lumen |
LT-1951 |
Polymer of L-arginine, the substrate for production of nitric oxide |
Prevention of |
Began Phase I/IIa PATENT trial to assess lumen loss in 50 patients undergoing saphenous vein coronary artery bypass graft surgery (3/22) |
Millennium |
Integrilin (FDA-approved) |
Eptifibide; glycoprotein IIb/IIIa inhibitor |
Cardiac conditions |
Final data from CLEAR Platelets trial showed drug plus clopidogrel provided superior platelet inhibition and prevention of heart muscle damage associated with elective coronary stenting vs. clopidogrel alone (3/1) |
Osiris |
Provacel |
Formulation of adult mesenchymal stem cells |
For use in |
Began a Phase I trial to evaluate safety and therapeutic benefits of treatment (3/31) |
The Medicines |
Clevelox |
Clevidipine; intravenous blood pressure control agent |
For use in |
Patient enrollment was suspended in the safety studies of its Phase III program after more frequent atrial fibrillation was seen in an interim analysis (3/28) |
Valentis Inc. |
VLTS-934 |
Non-ionic, block copolymer (poloxamer) |
Peripheral |
Began Phase IIb trial in 148 patients with intermittent claudication to assess improvement in exercise tolerance (3/31) |
CENTRAL NERVOUS SYSTEM | ||||
Aeolus |
AEOL 10150 |
Small-molecule catalytic antioxidant |
Amyotrophic lateral sclerosis |
Interim Phase I data showed that single doses were tolerated; no serious adverse events were reported (3/29) |
Amarin Corp. |
Miraxion (LAX-101c) |
Compound that inhibits certain enzymes, including phospholipases and caspases |
Depression |
Third Phase IIa trial showed superiority to placebo in a subgroup of 70 patients with melancholic characteristics (3/15) |
Guilford |
Aquavan |
Water-soluble prodrug of propofol |
Sedation |
Phase III trial in 278 patients met its primary endpoint of sedation, but trials are being suspended while lower dosing is investigated (3/24) |
Icagen Inc. |
ICA-69673 |
Compound that targets an ion channel expressed primarily in the central nervous system |
Epilepsy and neuropathic pain |
Phase I trials did not support further development of the compound (3/30) |
Ligand |
Avinza (FDA-approved) |
Extended-release morphine |
Chronic back pain |
ACTION trial in 393 patients showed better control of pain and improved sleep for drug vs. oxycodone CR (3/30) |
Ligand |
Avinza (FDA-approved) |
Extended-release morphine |
Osteoarthritis |
30-patient trial showed pain control and improved sleep (3/30) |
MediciNova Inc. |
MN-305 |
Serotonin type 1A receptor agonist |
Anxiety |
Began a Phase II trial expected to include 400 patients (3/1) |
New River |
NRP104 |
Prodrug of amphetamine |
Attention deficit hyperactivity disorder |
Phase II trial in 52 children demonstrated statistical significance vs. placebo on a ratings scale, the primary endpoint (3/1) |
Pain |
Oxytrex |
Oral agent combining a low dose of naltrexone (an opioid antagonist) with oxycodone (an opioid agonist) |
Pain |
Phase III trial in 719 patients with severe chronic low-back pain showed equal pain relief to oxycodone and about 20% fewer opioid-related side effects (3/24) |
Predix |
PRX-03140 |
Serotonin 4 (5-HT4) receptor agonist |
Alzheimer's disease |
Began Phase Ib trials to evaluate safety, tolerability and pharmacokinetics in 32 volunteers; a second study will include AD patients (3/30) |
Predix |
PRX-00023 |
Serotonin 1A (5HT1A) receptor agonist |
Generalized anxiety disorder |
Began Phase II trial to evaluate safety and tolerability of multiple doses in patients with moderate to severe GAD (3/8) |
Renovis Inc. |
REN-1654 |
Oral TNF-alpha release inhibitor |
Post-herpetic neuralgia |
Phase II trial in 954 patients did not reach statistical significance in its primary endpoint of change in daily spontaneous pain relief vs. placebo (3/7) |
Saegis |
SGS518 |
Selective antagonist of the 5-hydroxytryptamine-6 (5-HT6) serotonin receptor |
Schizophrenia |
Phase I trial in healthy volunteers showed the agent to be safe and well tolerated (3/29) |
Saegis |
SGS742 |
Selective, orally active GABA-B receptor antagonist |
Attention deficit hyperactivity disorder |
Began a Phase II trial to test the drugs in adults with ADHD (3/22) |
Savient |
Prosaptide |
A peptide derived from the human nerve growth protein prosaposin |
Peripheral neuropathic pain in HIV/AIDS patients |
Phase II trial was terminated after interim analysis showed there was little chance of attaining the analgesia efficacy endpoint (3/11) |
Targacept |
Ispronicline (TC-1734) |
Agonist at neuronal nicotinic acetylcholine receptors |
Cognitive and memory disorders |
An acceleration in brainwaves was observed in one Phase I trial, and positive effects on attention, learning and memory were seen in another Phase I trial (3/29) |
TheraQuest |
TQ-1011 |
Injectable formulation of the non-steroidal anti-inflammatory drug ketoprofen |
Postsurgical pain |
Phase II trial showed the drug was superior to placebo and IV morphine on all standard efficacy endpoints (3/30) |
Xenova Group |
TA-NIC |
Vaccine containing the protein conjugate nicotine butyric acid linked to recombinant cholera toxin B |
Nicotine addiction |
12-month data from 60 patients in a Phase I trial showed improved quit rates vs. placebo, as well as positive safety, tolerability and immunogenicity data (3/3) |
XenoPort Inc.* |
XP19986 |
Transported prodrug of R-baclofen |
Spasticity and |
Began Phase I trial to test safety and pharmacokinetics in healthy adults (3/23) |
DIABETES | ||||
AmCyte Inc. |
Islets for transplantation in microencapsulation technology |
Type I diabetes |
Transplanted first patient in a trial in Canada that is testing safety as well as the function of the cells (3/9) |
|
Generex |
Orallyn |
Oral insulin spray formulation |
Type I diabetes |
Open-label trial in 10 patients showed the product successfully replaced rapid-acting insulin (3/14) |
Metabasis |
CS-917 |
Fructose 1-6 bisphosphatase inhibitor |
Type II diabetes |
Partner Sankyo Co. Ltd. stopped two trials after seeing adverse events that involved apparent lactic acidosis in an interaction study with metformin; a Phase I trial is continuing (3/16) |
Metabolex Inc.* |
Metaglidasen (MBX-102) |
Oral insulin sensitizer |
Type II diabetes |
Phase II trial in 217 patients met the primary endpoint of reducing hemoglobin A1c, as well as secondary endpoints (3/22) |
Metabolex Inc.* |
MBX-2044 |
Oral insulin sensitizer; selective peroxisome proliferator-activated receptor modulator |
Type II diabetes |
Phase I trial showed the drug was well tolerated at all doses and reduced uric acid levels (3/3) |
Theratechnologies |
TH0318 |
Glucagon-like peptide-1 analogue |
Diabetes |
Phase I trial demonstrated safety and tolerability in 36 healthy volunteers (3/23) |
INFECTION | ||||
Advanced |
Inhibitor of tumor necrosis factor-alpha |
HIV |
Preliminary data from Phase I trial in nonresponding patients suggested a beneficial effect from inhibiting TNF-a (3/15) |
|
AnorMED Inc. |
AMD070 |
Agent targeting CXCR4 chemokine receptor to prevent HIV from entering healthy cells |
HIV |
Began Phase Ib/IIa trial in up to 48 patients to evaluate viral load, as well as safety and pharmaco-kinetics (3/16) |
Arpida Ltd.* |
Iclaprim (AR-100) |
A diaminopyrimidine; a broad-spectrum antibiotic |
Skin and soft- tissue infections |
Got OK for Phase III trial in the U.S. to compare safety and efficacy to linezolid (Zyvox) (3/16) |
Carrington |
GelVac |
Nasal powder vaccine delivery platform based on the GelSite polymer |
Vaccine delivery |
Began Phase I trial to assess nasal deposition of the powder as well as safety and nasal retention (3/15) |
ID Biomedical |
PGCvax |
Vaccine designed to be protective against all serotypes of pneumococci |
S. pneumoniae infections |
Analysis of Phase I trial showed the vaccine was well tolerated and immunogenic in different age groups; also, a Phase I trial in 75 infants was begun (3/22) |
StressGen |
HspE7 |
Fusion product consisting of heat-shock protein fused to human pappilomavirus antigen |
High-grade cervical dysplasia |
Phase II trial in 31 patients produced an overall response rate of 71%; 10 patients had a complete pathologic response (3/21) |
The Immune |
Remune |
Immune-based therapy comprising a whole-killed virus and an adjuvant |
HIV |
The drug will be used in an NIH trial in 92 patients to test the product with antiretroviral therapy vs. ART alone (3/29) |
Trimeris Inc. |
Fuzeon (FDA-approved) |
Enfuvirtide; HIV fusion inhibitor |
HIV |
Phase IIb trial showed benefit of drug as part of a regimen that includes an active boosted pro- tease inhibitor in previously treated patients; positive results also were seen in Phase III RESIST trial (3/1) |
ViroPharma |
Maribavir |
Benzimidazole compound; oral inhibitor of cytomeg-alovirus |
Prevention of CMV infection |
Phase I data showed the agent was well tolerated, had a good pharmacokinetic profile, and did not induce CYP3A (3/7) |
MISCELLANEOUS | ||||
Adolor |
Entereg |
Alvimopan capsules; mu opioid antagonist |
Chronic idiopathic constipation |
Phase IIb trial in the condition not due to opioid treatment failed to show a benefit vs. placebo (3/7) |
Adolor |
Entereg |
Alvimopan capsules; mu opioid antagonist |
Opioid-induced bowel dysfunction |
Phase IIa trial in 522 patients demonstrated statistically significant benefits in weekly frequency plc of spontaneous bowel movements (3/7) |
BioMarin |
rhASB (Aryplase) |
Galsulfase; an enzyme-replacement therapy |
Mucopoly- |
Phase III extension study in 38 patients showed continued improved endurance over weeks 24 to 48 (3/9) |
Critical |
Zyflo Filmtab |
Zileuton tablets; 5-lipoxygenase inhibitor |
Asthma |
Began Phase IIIb open-label study in patients who previously benefited from the drug; patients with mastocytosis also will be enrolled (3/14) |
Dynavax |
AIC |
Anti-allergy immunotherapy |
Ragweed allergy |
Phase I trial showed a clinically significant improvement in symptoms and a reduction in medication usage vs. placebo (3/21) |
GTx Inc. |
Ostarine |
Selective androgen receptor modulator |
Conditions associated with aging |
Phase I trial in 96 volunteers indicated the product appeared to be safe and well tolerated (3/15) |
ICOS Corp. |
IC485 |
Inhibitor of phosphodiesterase 4 |
Chronic obstructive pulmonary disease |
Phase II trial in 258 patients failed to demonstrate improved lung function vs. placebo (3/23) |
Indevus |
Sanctura (FDA-approved) |
Trospium chloride; anti-cholinergic compound; muscarinic receptor antagonist |
Overactive bladder |
Indevus and partner Odyssey Pharmaceuticals Inc. began a Phase IV trial to evaluate safety and efficacy (3/15) |
Lantibio Inc.* |
Moli1901 |
Duramycin; polycyclic peptide that targets phospholipid phosphati-dylethanolamine |
Dry-eye syndrome |
Began a Phase I trial of the product (3/15) |
MediciNova |
MN-001 |
Leukotriene receptor antagonist and inhibitor of phosphodiesterases III and IV, 5-lipoxygenase and thromboxane A2 |
Asthma |
Began a Phase II trial (3/28) |
MediciNova |
MN-221 |
Selective beta-2 agonist |
Management of preterm labor |
Began Phase I trial that will assess safety and dosing (3/14) |
Neurocrine |
NBI-56418 |
Small-molecule gonad-otropin-releasing hormone receptor antagonist |
Endometriosis |
Phase I trial in 60 healthy pre-menopausal women demonstrated safety and tolerability, and suppression of estradiol (3/2) |
Nymox |
NX-1207 |
Investigational drug for BPH |
Benign prostatic hyperplasia |
Phase I and II trials showed a statistically significant overall mean symptom improvement after 30 days (3/22) |
Palatin |
PT-141 |
Intranasally delivered melanocortin agonist |
Erectile dysfunction |
Trial with Viagra in ED patients showed improved duration of erectile activity vs. Viagra alone (3/18) |
Progenics |
MNTX |
Methylnaltrexone; agent designed to block peripheral opioid receptors |
Opioid-induced constipation |
Pivotal Phase III trial in 154 patients demonstrated statistically significant induction of laxation within four hours, the primary endpoint (3/10) |
Targeted |
tgAAVCF |
Gene therapy that uses an adeno- associated virus vector to deliver the CFTR gene directly into the lungs |
Cystic fibrosis |
Phase II trial in 120 patients failed to meet its primary endpoint of improving lung function vs. placebo; further development is not planned (3/17) |
Notes: | ||||
* Privately held. | ||||
BLA = Biologics license application; FDA = Food and Drug Administration; IND = Investigational new drug application; NDA = New drug application; SPA = Special protocol assessment. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; NYSE = New York Stock Exchange; OSE = Osaka Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.